Drug intelligence / Profile preview

PLD-105

Development stage: Preclinical
Lead developer: Pelemed

Overview

PLD-105 is an investigational therapeutic candidate being developed by Pelemed for the treatment of solid tumors that have failed to respond to standard anti-PD-1 checkpoint inhibitor therapy. Currently in the discovery stage, the drug is designed to target the PD-1 pathway or associated resistance mechanisms to restore or enhance anti-tumor immune responses in patients who are refractory to existing immunotherapies. While the specific molecular modality has not been disclosed, the program aims to address a significant unmet need in oncology by overcoming primary or acquired resistance to PD-1/PD-L1 blockade.

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on PLD-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLD-105.

Explore the full profile